Format

Send to

Choose Destination
See comment in PubMed Commons below
BMC Cancer. 2016 Aug 19;16:652. doi: 10.1186/s12885-016-2710-6.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

Author information

1
Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA. david_steensma@dfci.harvard.edu.
2
Division of Hematology and Oncology, University of California, Davis, Comprehensive Cancer Center, Sacramento, CA, USA.
3
Division of Hematology and Oncology, University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
4
Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA.
5
Department of Pathology, University of New Mexico, Albuquerque, NM, USA.
6
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
7
Hematology, North Shore University Health System, Evanston, IL, USA.
8
Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA.
9
Yale School of Public Health, New Haven, CT, USA.
10
Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, USA.
11
Division of Hematology, University of Colorado Cancer Center, Aurora, CO, USA.
12
Division of Hematology/Oncology, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
13
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
14
Department of Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA.
15
Aurora Research Institute, Aurora Health Care, Milwaukee, WI, USA.
16
Celgene Corporation, Summit, NJ, USA.
17
Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.

Abstract

BACKGROUND:

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are myeloid neoplasms in which outgrowth of neoplastic clones disrupts normal hematopoiesis. Some patients with unexplained persistent cytopenias may not meet minimal diagnostic criteria for MDS but an alternate diagnosis is not apparent; the term idiopathic cytopenia of undetermined significance (ICUS) has been used to describe this state. MDS and AML occur primarily in older patients who are often treated outside the clinical trial setting. Consequently, our understanding of the patterns of diagnostic evaluation, management, and outcomes of these patients is limited. Furthermore, there are few natural history studies of ICUS. To better understand how patients who have MDS, ICUS, or AML are managed in the routine clinical setting, the Connect MDS/AML Disease Registry, a multicenter, prospective, observational cohort study of patients newly diagnosed with these conditions has been initiated.

METHODS/DESIGN:

The Connect MDS/AML Disease Registry will capture diagnosis, risk assessment, treatment, and outcomes data for approximately 1500 newly diagnosed patients from approximately 150 community and academic sites in the United States in 4 cohorts: (1) lower-risk MDS (International Prognostic Scoring System [IPSS] low and intermediate-1 risk), with and without del(5q); (2) higher-risk MDS (IPSS intermediate-2 and high risk); (3) ICUS; and (4) AML in patients aged ≥ 55 years (excluding acute promyelocytic leukemia). Diagnosis will be confirmed by central review. Baseline patient characteristics, diagnostic patterns, treatment patterns, clinical outcomes, health economics outcomes, and patient-reported health-related quality of life will be entered into an electronic data capture system at enrollment and quarterly for 8 years. A tissue substudy to explore the relationship between karyotypes, molecular markers, and clinical outcomes will be conducted, and is optional for patients.

DISCUSSION:

The Connect MDS/AML Disease Registry will be the first prospective, observational, non-interventional study in the United States to collect clinical information, patient-reported outcomes, and tissue samples from patients with MDS, ICUS, or AML receiving multiple therapies. Results from this registry may provide new insights into the relationship between diagnostic practices, treatment regimens, and outcomes in patients with these diseases and identify areas for future investigation.

TRIAL REGISTRATION:

Connect MDS/AML Disease Registry ( NCT01688011 ). Registered 14 September 2012.

KEYWORDS:

Acute myeloid leukemia; Biomarkers; Clinical outcomes; Clonal hematopoiesis of indeterminate potential (CHIP); Idiopathic cytopenia of undetermined significance; Myelodysplastic syndromes; Patient-reported outcomes; Registry; Treatment patterns

PMID:
27538433
PMCID:
PMC4991094
DOI:
10.1186/s12885-016-2710-6
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center